MindMaze Therapeutics Holding SA risk profile
54 Elevated one input has moved against it
Measured 22 September 2026 from V6M's filed statements. Recomputed nightly.
54 (Elevated), driven by Cash conversion at 100, over 5 weighted categories on the GENERAL profile.
What is measured
| Mechanism | Reading | Band | Direction | Driver |
|---|---|---|---|---|
| Market expectation | 85 | Acute | Stable | Drawdown from the 52-week high — 94.7% |
| Operating pressure | 0 | Contained | Stable | Costs outgrowing revenue — -76.3 percentage points |
| Cash conversion | 100 | Acute | Stable | Capital spending against operating cash — -0.06x |
| Leverage and coverage | 37 | Normal | Stable | Interest cover — -77.12x |
| Competitive position | 49 | Elevated | Stable | Operating-margin gap against peers — -79.1 percentage points |
| Concentration | Reads identified supplier spend, customers above the 10% disclosure threshold and revenue by region. No reading is stored for this company. | |||
These are descriptive readings of disclosed mechanisms, not investment advice, and not a prediction. A band says where a measured input sits, never what to do about it or what happens next.
Financial Services companies with a risk reading
Visa Inc - Class A 23Mastercard Incorporated - Class A 42BlackRock Finance Inc 52S&P Global Inc 46Marsh & McLennan Cos. Inc 41Aon plc. - Class A 38Arthur J. Gallagher & Company 51London Stock Exchange Group PLC 40Nasdaq Inc - 144A 54Coinbase Global Inc - Class A 62PayPal Holdings Inc 55Interactive Brokers Group Inc - Class A 39
Financials, valuation and price history for MindMaze Therapeutics Holding SA